Repros Therapeutics, Inc. (RPRX) Posts Wider than Expected Q2 Loss of 21c/Share

August 13, 2012 9:26 AM

Repros Therapeutics, Inc. (NASDAQ: RPRX) reported Q2 EPS of ($0.21), $0.02 worse than the analyst estimate of ($0.19).

For earnings history and earnings-related data on Repros Therapeutics, Inc. (RPRX) click here.

No results found